Qlaris Bio, a clinical-stage biotechnology company targeting unmet needs in debilitating ophthalmic diseases, today announced that it has closed a $24 million Series B financing round. Co-led by Canaan and New Leaf Venture Partners, the financing also included new participation from funds managed by abrdn Inc., as well as existing investors Mayo Clinic Ventures and Correlation Ventures.Qlaris Bio was founded in August 2019 with a singular focus: to develop novel, innovative therapies with first-in-class mechanisms of action to address serious and debilitating ophthalmic diseases.

Qlaris Bio是一家临床阶段的生物技术公司，针对衰弱性眼科疾病的未满足需求，今天宣布已完成2400万美元的B轮融资。在迦南和New Leaf Venture Partners的共同领导下，融资还包括来自abrdn Inc.管理的基金以及现有投资者Mayo Clinic Ventures和Correlation Ventures的新参与。Qlaris Bio成立于2019年8月，专注于开发新颖的创新疗法，采用一流的行动机制来解决严重和衰弱的眼科疾病。

The company's lead program, QLS'111, uses ATP-sensitive potassium channel modulators that improve outflow through distal vascular tissues of the eye to reduce IOP..

该公司的领先项目QLS'111使用ATP敏感的钾通道调节剂，可改善通过眼睛远端血管组织的流出，从而降低眼压。